Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009, Article ID 831626, 9 pages
http://dx.doi.org/10.1155/2009/831626
Research Article

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy

1Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany
2Department of Internal Medicine II, University of Würzburg, 97080 Würzburg, Germany
3Department of Surgery, University of Würzburg, 97080 Würzburg, Germany
4Institute of Pathology, Ostalb-Klinikum Aalen, 73430 Aalen, Germany
5Department of Internal Medicine , Ostalb-Klinikum Aalen, 73430 Aalen, Germany

Received 30 August 2009; Revised 9 November 2009; Accepted 31 December 2009

Academic Editor: Francis Seow-Choen

Copyright © 2009 S. Gattenlöhner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. R. Jass, “Colorectal cancer: a multipathway disease,” Critical Reviews in Oncogenesis, vol. 12, no. 3-4, pp. 273–287, 2006. View at Google Scholar
  3. F. Ciardiello and G. Tortora, “Drug therapy: EGFR antagonists in cancer treatment,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1160–1174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. N. A. Reynolds and A. J. Wagstaff, “In the treatment of metastatic colorectal cancer,” Drugs, vol. 64, no. 1, pp. 109–118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. C. S. Karapetis, S. Khambata-Ford, D. J. Jonker et al., “K-ras mutations and benefit from cetuximab in advanced colorectal cancer,” The New England Journal of Medicine, vol. 359, no. 17, pp. 1757–1765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Boige, D. Malka, J. Taieb, J.-P. Pignon, and M. Ducreux, “Colorectal cancer: prognostic molecular markers,” Gastroenterologie Clinique et Biologique, vol. 28, no. 1, pp. 21–32, 2004. View at Google Scholar · View at Scopus
  8. J. H. van Krieken, A. Jung, T. Kirchner et al., “KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program,” Virchows Archiv, vol. 453, no. 5, pp. 417–431, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Benvenuti, A. Sartore-Bianchi, F. Di Nicolantonio et al., “Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies,” Cancer Research, vol. 67, no. 6, pp. 2643–2648, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. C. J. Allegra, J. M. Jessup, M. R. Somerfield et al., “American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2091–2096, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Loupakis, L. Pollina, I. Stasi et al., “PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 16, pp. 2622–2629, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Artale, A. Sartore-Bianchi, S. M. Veronese et al., “Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4217–4219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Tortola, R. Steinert, M. Hantschick et al., “Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer,” Journal of Clinical Oncology, vol. 19, no. 11, pp. 2837–2843, 2001. View at Google Scholar · View at Scopus
  14. B. Suchy, C. Zietz, and H. M. Rabes, “K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis,” International Journal of Cancer, vol. 52, no. 1, pp. 30–33, 1992. View at Google Scholar · View at Scopus
  15. F. Al-Mulla, J. J. Going, E. T. Sowden, A. Winter, I. R. Pickford, and G. D. Birnie, “Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality,” Journal of Pathology, vol. 185, no. 2, pp. 130–138, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J. Oudejans, R. J. C. Slebos, F. A. N. Zoetmulder, W. J. Mooi, and S. Rodenhuis, “Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver,” International Journal of Cancer, vol. 49, no. 6, pp. 875–879, 1991. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Gattenlohner, C. Germer, and H. K. Muller-Hermelink, “K-ras mutations and cetuximab in colorectal cancer,” The New England journal of medicine, vol. 360, no. 8, pp. 835–836, 2009. View at Google Scholar · View at Scopus
  18. C. R. Antonescu, “Targeted therapies in gastrointestinal stromal tumors,” Seminars in Diagnostic Pathology, vol. 25, no. 4, pp. 295–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Apice, A. Milano, G. S. Bruni, R. V. Iaffaioli, and F. Caponigro, “Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives,” Reviews on Recent Clinical Trials, vol. 1, no. 1, pp. 35–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Bonavida, “Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions,” Oncogene, vol. 26, no. 25, pp. 3629–3636, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Santini, F. Loupakis, B. Vincenzi et al., “High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice,” Oncologist, vol. 13, no. 12, pp. 1270–1275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Oliveira, S. Velho, C. Moutinho et al., “KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression,” Oncogene, vol. 26, no. 1, pp. 158–163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Al-Mulla, J. J. Going, E. T. Sowden, A. Winter, I. R. Pickford, and G. D. Birnie, “Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality,” Journal of Pathology, vol. 185, no. 2, pp. 130–138, 1998. View at Publisher · View at Google Scholar · View at Scopus